• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过使用电子健康记录的基于图的框架识别阿尔茨海默病进展亚表型。

Identifying Alzheimer's Disease Progression Subphenotypes via a Graph-based Framework using Electronic Health Records.

作者信息

Huang Yu, Xu Jie, Fan Zhengkang, Hu Yu, He Xing, Chen Aokun, Liu Yuxi, Yin Rui, Guo Jingchuan, DeKosky Steven T, Jaffee Michael, Zhou Manqi, Su Chang, Wang Fei, Guo Yi, Bian Jiang

机构信息

Indiana University.

University of Florida.

出版信息

Res Sq. 2025 Apr 7:rs.3.rs-6257332. doi: 10.21203/rs.3.rs-6257332/v1.

DOI:10.21203/rs.3.rs-6257332/v1
PMID:40297697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12036456/
Abstract

PURPOSE

Understanding the heterogeneity of neurodegeneration in Alzheimer's disease (AD) development, as well as identifying AD progression pathways, is vital for enhancing diagnosis, treatment, prognosis, and prevention strategies. To identify disease progression subphenotypes in patients with mild cognitive impairment (MCI) and AD using electronic health records (EHRs).

METHODS

We identified patients with mild cognitive impairment (MCI) and AD from the electronic health records from the OneFlorida+ Clinical Research Consortium. We proposed an outcome-oriented graph neural network-based model to identify progression pathways from MCI to AD.

RESULTS

Of the included 2,525 patients, 61.66% were female, and the mean age was 76. In this cohort, 64.83% were Non-Hispanic White (NHW), 16.48% were Non-Hispanic Black (NHB), and 2.53% were of other races. Additionally, there were 274 Hispanic patients, accounting for 10.85% of the total patient population. The average duration from the first MCI diagnosis to the transition to AD was 891 days. We identified four progression subphenotypes, each with distinct characteristics. The average progression times from MCI to AD varied among these subphenotypes, ranging from 805 to 1,236 days.

CONCLUSION

The findings suggest that AD does not follow uniform transitions of disease states but rather exhibits heterogeneous progression pathways. Our proposed framework holds the potential to identify AD progression subphenotypes, providing valuable and explainable insights for the development of the disease.

摘要

目的

了解阿尔茨海默病(AD)发展过程中神经退行性变的异质性,并确定AD的进展途径,对于加强诊断、治疗、预后和预防策略至关重要。利用电子健康记录(EHR)识别轻度认知障碍(MCI)和AD患者的疾病进展亚表型。

方法

我们从OneFlorida+临床研究联盟的电子健康记录中识别出轻度认知障碍(MCI)和AD患者。我们提出了一种基于结果导向的图神经网络模型,以识别从MCI到AD的进展途径。

结果

在纳入的2525名患者中,61.66%为女性,平均年龄为76岁。在这个队列中,64.83%为非西班牙裔白人(NHW),16.48%为非西班牙裔黑人(NHB),2.53%为其他种族。此外,有274名西班牙裔患者,占患者总数的10.85%。从首次MCI诊断到转变为AD的平均持续时间为891天。我们确定了四种进展亚表型,每种都有不同的特征。这些亚表型从MCI到AD的平均进展时间各不相同,从805天到1236天不等。

结论

研究结果表明,AD并非遵循疾病状态的统一转变,而是表现出异质性的进展途径。我们提出的框架有潜力识别AD进展亚表型,为该疾病的发展提供有价值且可解释的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/89293bc7011f/nihpp-rs6257332v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/7405c6e6238e/nihpp-rs6257332v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/0b41fae8540d/nihpp-rs6257332v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/60308788b26f/nihpp-rs6257332v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/f3f4c779b574/nihpp-rs6257332v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/26e74796c717/nihpp-rs6257332v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/89293bc7011f/nihpp-rs6257332v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/7405c6e6238e/nihpp-rs6257332v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/0b41fae8540d/nihpp-rs6257332v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/60308788b26f/nihpp-rs6257332v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/f3f4c779b574/nihpp-rs6257332v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/26e74796c717/nihpp-rs6257332v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c014/12036456/89293bc7011f/nihpp-rs6257332v1-f0006.jpg

相似文献

1
Identifying Alzheimer's Disease Progression Subphenotypes via a Graph-based Framework using Electronic Health Records.通过使用电子健康记录的基于图的框架识别阿尔茨海默病进展亚表型。
Res Sq. 2025 Apr 7:rs.3.rs-6257332. doi: 10.21203/rs.3.rs-6257332/v1.
2
Identifying progression subphenotypes of Alzheimer's disease from large-scale electronic health records with machine learning.利用机器学习从大规模电子健康记录中识别阿尔茨海默病的进展亚表型。
J Biomed Inform. 2025 May;165:104820. doi: 10.1016/j.jbi.2025.104820. Epub 2025 Apr 1.
3
Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer's Disease Using Electronic Health Records.利用电子健康记录从轻度认知障碍到阿尔茨海默病识别以结果为导向的进展亚型
medRxiv. 2023 Aug 4:2023.07.27.23293270. doi: 10.1101/2023.07.27.23293270.
4
Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer's Disease Using Electronic Health Records.基于电子健康记录的轻度认知障碍向阿尔茨海默病进展的结局导向亚组识别。
AMIA Annu Symp Proc. 2024 Jan 11;2023:764-773. eCollection 2023.
5
Graph Convolutional Network for AD and MCI Diagnosis Utilizing Peripheral DNA Methylation: Réseau de neurones en graphes pour le diagnostic de la MA et du TCL à l'aide de la méthylation de l'ADN périphérique.利用外周血DNA甲基化的阿尔茨海默病和轻度认知障碍诊断的图卷积网络:使用外周血DNA甲基化进行阿尔茨海默病和轻度认知障碍诊断的图神经网络
Can J Psychiatry. 2024 Dec;69(12):869-879. doi: 10.1177/07067437241300947. Epub 2024 Nov 25.
6
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217.血浆p-tau217揭示轻度认知障碍的病因异质性及进展为痴呆症的风险。
J Prev Alzheimers Dis. 2025 Jan;12(1):100011. doi: 10.1016/j.tjpad.2024.100011. Epub 2025 Jan 1.
7
AD-BERT: Using pre-trained language model to predict the progression from mild cognitive impairment to Alzheimer's disease.AD-BERT:利用预训练语言模型预测从轻度认知障碍到阿尔茨海默病的进展。
J Biomed Inform. 2023 Aug;144:104442. doi: 10.1016/j.jbi.2023.104442. Epub 2023 Jul 8.
8
Federated learning with multi-cohort real-world data for predicting the progression from mild cognitive impairment to Alzheimer's disease.利用多队列真实世界数据进行联邦学习以预测从轻度认知障碍到阿尔茨海默病的进展
Alzheimers Dement. 2025 Apr;21(4):e70128. doi: 10.1002/alz.70128.
9
A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.一种参数高效的深度学习方法,用于预测轻度认知障碍向阿尔茨海默病的转化。
Neuroimage. 2019 Apr 1;189:276-287. doi: 10.1016/j.neuroimage.2019.01.031. Epub 2019 Jan 14.
10
Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.从正常认知到轻度认知障碍及痴呆阶段估算阿尔茨海默病的进展速度。
Curr Alzheimer Res. 2018;15(8):777-788. doi: 10.2174/1567205015666180119092427.

本文引用的文献

1
Characterizing the progression from mild cognitive impairment to dementia: a network analysis of longitudinal clinical visits.从轻度认知障碍到痴呆的进展特征:纵向临床就诊的网络分析。
BMC Med Inform Decis Mak. 2024 Oct 18;24(1):305. doi: 10.1186/s12911-024-02711-z.
2
Stratifying heart failure patients with graph neural network and transformer using Electronic Health Records to optimize drug response prediction.基于电子健康记录,使用图神经网络和转换器对心力衰竭患者进行分层,以优化药物反应预测。
J Am Med Inform Assoc. 2024 Aug 1;31(8):1671-1681. doi: 10.1093/jamia/ocae137.
3
Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer's disease reveals distinct sequential responses to Aβ and tau.
阿尔茨海默病时空进展过程中大脑髓系细胞转录组图谱揭示了对 Aβ 和 tau 的不同顺序反应。
Acta Neuropathol. 2024 Apr 1;147(1):65. doi: 10.1007/s00401-024-02704-2.
4
Disease staging of Alzheimer's disease using a CSF-based biomarker model.采用基于脑脊液生物标志物模型对阿尔茨海默病进行疾病分期。
Nat Aging. 2024 May;4(5):694-708. doi: 10.1038/s43587-024-00599-y. Epub 2024 Mar 21.
5
Identification of Outcome-Oriented Progression Subtypes from Mild Cognitive Impairment to Alzheimer's Disease Using Electronic Health Records.基于电子健康记录的轻度认知障碍向阿尔茨海默病进展的结局导向亚组识别。
AMIA Annu Symp Proc. 2024 Jan 11;2023:764-773. eCollection 2023.
6
Reducing the Risk of Dementia in Atrial Fibrillation.降低心房颤动患者患痴呆症的风险
JACC Asia. 2023 Oct 17;3(5):787-789. doi: 10.1016/j.jacasi.2023.09.001. eCollection 2023 Oct.
7
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.NAD在不同临床情况下的安全性和有效性评估:一项系统综述。
Am J Physiol Endocrinol Metab. 2024 Apr 1;326(4):E417-E427. doi: 10.1152/ajpendo.00242.2023. Epub 2023 Nov 16.
8
Age at Diagnosis of Atrial Fibrillation and Incident Dementia.心房颤动诊断时的年龄与痴呆症发病风险。
JAMA Netw Open. 2023 Nov 1;6(11):e2342744. doi: 10.1001/jamanetworkopen.2023.42744.
9
Lipoprotein Metabolism, Protein Aggregation, and Alzheimer's Disease: A Literature Review.脂蛋白代谢、蛋白质聚集与阿尔茨海默病:文献综述
Int J Mol Sci. 2023 Feb 2;24(3):2944. doi: 10.3390/ijms24032944.
10
Machine learning enabled subgroup analysis with real-world data to inform clinical trial eligibility criteria design.机器学习支持使用真实世界数据进行亚组分析,为临床试验纳入标准设计提供信息。
Sci Rep. 2023 Jan 12;13(1):613. doi: 10.1038/s41598-023-27856-1.